BT8009

About Bicycle Therapeutics

Bicycle Therapeutics is a UK-based, NASDAQ-listed biotech pioneering a novel class of synthetic, constrained peptide therapeutics. Its core Bicycle® platform generates molecules designed to deliver the high specificity of biologics with the favorable pharmacokinetics of small molecules, enabling deep tissue penetration in solid tumors. The company has advanced multiple wholly-owned and partnered programs into clinical development, focusing on oncology targets like Nectin-4 and EphA2, while actively exploring partnerships to expand into other therapeutic areas. Its strategy is to build a leading solid tumor medicine portfolio, validated by clinical data and strategic collaborations.

Therapeutic Areas